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ntigena key role in IgG antibody homeostasis and affects its pharmacokinetic properties. An in vitr
binding assay could be a highly valuable complementary tool to assess IgG an
pharmacokinetics in IgG engineering and screening during the early optimization st
addition, it could be useful in biological characterization studies for antibody minor va
process optimization, and comparability study at later stages of antibody development.
Here we developed a homogeneous AlphaScreen-based FcRn assay to assess the binding o
to IgG antibody in vitro. The assay is found to be accurate, precise, specific, and simple:
beads loaded with FcRn and acceptor beads loaded with IgG1 mAb1 are mixed togethe
sample IgG at various dilutions and incubated for 1 h before acquiring data with a fluore
reader. This assay can run up to four samples per plate in 2 h, which is time and cost ef
comparedwith other FcRn bindingmethods such as cell-based fluorescent-activated cell sc
surface plasma resonance. Our data demonstrated that this assay is suitable for assessing th
binding in vitro andprovides a platformapproach that canbe readily applied to various anti
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC B
ND license (http://creativecommons.org/licenses/by-nc-nd
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nizes the target of the antibody, while the Fc dom
predominately responsible for non-target-associated in
tions such as effector functionsmediated by Fc receptors an
(Jiang et al., 2011). Among several Fc receptors known to in
with IgG antibodies, neonatal Fc receptor (FcRn) plays a c
role in maintaining IgG homeostasis (Kacskovics et al.,
After IgG binds to its target on the cell surface, it is pinocyto
the endosomewhere FcRn binds to the CH2–CH3 junction
mAb at pH 6 and recycles themAb back into circulation at
(Burmeister et al., 1994; Rodewald and Kraehenbuhl,
Roopenian and Akilesh, 2007; Ying et al., 2014). Th
dependency of FcRn binding comes mostly from his
residues His 310, His 435, and His 436 of IgG, whic
protonated at pH 6 creating a strong interaction wit
anionic pocket of FcRn; they are neutralized at pH 7.4 rel
IgG from FcRn (Medesan et al., 1997; Shields et al., 2
While FcRn-bound IgGs are protected and rescued
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FcRn binding affects the level of IgG in vivo, many resea
are currently investigating the relationship between
affinity and the pharmacokinetic properties of IgG to
understand IgG homeostasis. Recent studies showed th
homeostasis is a complicated process that is affect
antibody characteristics and its therapeutic target as w
FcRn binding (Gurbaxani et al., 2006, 2013; Suzuki
2010; Wang et al., 2011). Still, it is clear that FcRn is c
for IgG homeostasis in vivo (Kacskovics et al., 2011; Ku
Aveson, 2011; Zalevsky et al., 2010). As such, a tool to
the in vitro binding of FcRn to IgG is needed, so that it c
used to engineer and screen FcRn-IgG interaction to im
the efficacy and dosing strategies for therapeutic mA
addition, it can be used in characterization studies o
antibodies.
There are several types of FcRn binding assays, inc
cell-based fluorescent-activated cell scan (FACS) assay
those that are non-cell based such as enzyme-linked imm
sorbent assay (ELISA) and surface plasmon resonance
analysis. ELISA immobilizes FcRn (or IgG) on a plate and d
IgG (or FcRn) captured with secondary antibody conju
with horseradish peroxidase or other enzymes (Ebersbac
Proetzel, 2012; Lu et al., 2011). SPR is a widely used meth
detect FcRn binding of IgG without any tag measuring bo
and koff (Bertolotti-Ciarlet et al., 2009; Magistrelli et al.,
Stapleton et al., 2011; Wang et al., 2011). The cell-based
assay uses cells expressing FcRn on the surface and label
to measure the affinity (Hinton et al., 2005; Mathur
2013). While there are several assay formats available, th
still room for improvements for sensitivity, reproduci
consistency, as well as time requirements and cost.
Here, we describe the development of a homog
AlphaScreen® -based FcRn binding assay as a general
assay format, and we characterize the method. AlphaS
technology provides sensitive detection of the low-a
binding interaction between FcRn and IgGwithout needin
wash or secondary reagent, which could be a challenge
typical ELISA methods.
The AlphaScreen-based FcRn binding assay is a simp
quickmethod that can beused tomeasure FcRn binding o
FcRn-loaded donor beads and IgG1 mAb1-loaded ac
beads are mixed together at once with various dilutio
sample IgG and simply incubated for 1 h before being
on a fluorescence reader. Up to four different samples c
tested in the same plate in 2 h by sharing donor and acc
beads. The assay is accurate, precise and stability-indi
when critical residues for FcRn binding on the antibod
modified. The assay is also able to capture the impa
antibody Fab region on FcRn binding and the assay f
was found to be readily applied to other antibodies
minimal modifications.
2. Materials and methods
2.1. Materials
mAb1, mAb2, mAb4, and mAb5 are IgG1 mono
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prepared as described previously (Schlothauer et al., 2013
used to prepare biotinylated hFcRn.
2.2. Preparation of biotinylated FcRn
BioA kit: Biotin-Protein Ligase (BirA) was purchased
Avidity, LLC (Aurora, CO; #BirA500). Biotinylation
performed following the manufacture's instruction.
2.3. Conjugation of acceptor beads with antibody
AlphaScreen unconjugated acceptor beads (1mg; #67
PerkinElmer,Waltham,MA)were centrifuged and re-susp
in labeling solution (DPBS containing 2.2 mMNaBHCN an
polysorbate 20) before adding suitable amount of antibody
conjugated. The mixture was then incubated for 16–20
37 °C with continuous shaking. The conjugation reactio
quenched by adding 600 mM of O-(carboxymethyl) hyd
amine hemihydrochloride (CMO;#C13408-10G, Sigma-Al
and further incubating the mixture at 37 °C for 1 h
continuous shaking. At the end of the incubation, the an
conjugated acceptor beads were centrifuged and re-susp
in PBS.
2.4. AlphaScreen-based FcRn binding assay
Briefly, first the test sample was diluted and loade
each well of a 96-well 1/2 area plate (#6005560, PerkinE
Streptavidin-coated donor beads (#6760002, PerkinE
was diluted in assay diluent (50 μM in 100 mM so
phosphate, 25 mM NaCl, pH 6.0, and 0.02% polysorba
containing biotinylated FcRn, then added to each well
96-well 1/2 area plate and shaken for 1–2 min. The an
conjugated acceptor beads were also diluted (50 μM) in
diluent before being added to each well. After an incubat
about one hour, the fluorescent signal was obtained o
EnVision® 2104 Multilabel Plate Reader (PerkinElmer)
excitation at 680 nm and reading emission at 520–620 nm
fluorescent signals of the reference material and the sa
were plotted against concentrations using a four-para
curve-fitting program (SoftMax Pro).
Relative binding activities were calculated by dividin
half maximal effective concentration (EC50) of the refe
material by the EC50 of the samples.
3. Results and discussion
3.1. Development and characterization of the AlphaScreen
FcRn binding assay
A homogenous AlphaScreen-based method was succe
ly developed for measuring antibody's binding to FcRn
easy, simple, quick, robust method with high-through
useful for both IgG screening and biological characteri
studies.
In this study using the AlphaScreen-based assay, bio
ated FcRn is loaded to donor beads, and IgG1mAb1 is loa
acceptor beads. Without the addition of any external IgG
binds to IgG1 mAb1, and the close proximity enable
transfer of 1O2 from donor beads excited at 680 nm to acceptor
beads emitting a signal at 520–620 nm (Fig. 1). Upon the
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Table 1
Precision and accuracy of AlphaScreen-based FcRn binding assay.
Expected relative
binding (%)
Measured relative
binding (%)
mean ± SD (n = 5)
Accuracy (%) Inter-assay
coefﬁcient of
variation (%)
70 67 ± 4 96 6
100 95 ± 9 95 9
132 125 ± 14 95 11
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IgG to FcRn results in a different emitting signal for dif
sample IgG dilutions. From the competitive direct bindin
of reference material and samples, the relative FcRn bind
sample IgGs was calculated. This assay can run up to
samples per plate in 2 h, which is time and cost eff
compared to other FcRn binding methods such as cell-
fluorescent-activated cell scan and surface plasma reson
We further characterized the assay by conducting a st
evaluate the assay accuracy and precision. Briefly, mAb
diluted to nominal concentrations of 0.7, 1.0, and 1.3 m
corresponding to 70%, 100%, and 130% of the target conc
tion of 1.0 mg/mL, respectively. The protein concentrati
the dilutions were determined accurately by an ultra
spectrophotometric scan. The measured concentration o
sample was 0.698, 1.000, and 1.319 mg/mL, respectively
samplewas subsequently diluted further into assay diluen
tested as described in Section 2.3. Each sample was assa
five independent assays. To assess the accuracy of the assa
measured activities were divided by the expected activiti
expressed as percentage recoveries. The mean activit
three tested concentrations were 67%, 95%, and 125%, re
tively, which represents percentage recoveries ranging
95–96%. The inter-assay variability (relative standard
tion) was 6–11% (Table 1).
In addition to method accuracy and precision, its spec
was also evaluated. When one IgG1 molecule with Fc r
(mAb1) and another without Fc region (IgG1 Fab, mAb3)
tested side by side, the IgG1 molecule with Fc showed a
dependent response curve, but the IgG1 molecule with
region (mAb3) did not show any response (Fig. 2)
demonstrated that the method is specific for the IgG mo
with Fc region.
After the method accuracy, precision, and specificity
characterized, the ability of the assay to detect changes
domain modification was evaluated using a panel of str
mAb1 samples that had been subjected to various chemic
physical treatments, such as oxidation, elevated temper
pH, and light. Each sample was diluted in the assay diluen
tested in three assays according to the method proc
described in Section 2.3. The activities of the str
samples were normalized to the activity of the correspoFig. 1. AlphaScreen-b,
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basic pH, extended light exposure, and treatment with
2,2′-azobis(2-amidinopropane) dihydrochloride (AAPH
activities similar to their respective controls.
The mAb1 samples treated with 10 mM AAPH or acid
which had higher level of antibody HMWS demons
increased binding activity to FcRn. That is consistent with
was observed in other FcRn binding methods such as s
plasmon resonance (SPR) assays and the analytical
affinity chromatography (Lu et al., 2011; Mathur et al.,
Schlothauer et al., 2013). The antibody aggregates or H
were found to exhibit a highly increased response sign
the slow off-rate in SPR, and longer retention time
monomeric IgG in the FcRn affinity column (Schlot
et al., 2013). This stronger interaction of HMWS with F
probably due to avidity effects of the Fc parts. Furtherm
the AlphaScreen-based method, strong correlation wa
served between FcRn binding and the level of HMWS as s
in the insert of Fig. 3A. This evidence demonstrates th
AlphaScreen-based method can distinguish aggregation
ucts from monomeric IgG. As with findings from
methods, the presence of HMWS should be considered
interpreting FcRn binding data.
Oxidation of Met252 and Met428 impairs bindi
antibodies to FcRn and negatively affect PK (Liu et al.,
Schlothauer et al., 2013; Stracke et al., 2014). Ther
antibody samples under different oxidation treatment
analyzed in the AlphaScreen-based method. For mAb1 tr
with 1% H2O2, reverse phase HPLC data revealed
approximately 99.6% of the heavy chains were oxidized
exclusion analysis of the untreated control and 1%
stressed samples demonstrated comparable level of aggr
(0.2% vs 0.3%). When this stressed sample was testedased FcRn binding assay scheme.
AlphaScreen-based method, the estimated FcRn binding was
about 4% comparedwith the untreated control sample (Fig. 3A)
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Fig. 2. Specificity of FcRn binding to IgG Fc. IgG Fc is mAb1 (open circles) and IgG1 Fab is Fab fragment from mAb3 (filled triangles).
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able to detect the oxidation of the Fc Met residues imp
FcRn binding.
For the control and samples treated with 3mM, and 1
AAPH, the oxidation level ofMet 252 varied from7% to 30
the oxidation level ofMet 428 varied from 4% to 21%.Wh
oxidation in these positions is known to reduce the bind
Fc to FcRn (Pan et al., 2009; Mathur et al., 2013; Stracke
2014), increased FcRn binding was observed for
AAPH-treated samples in the AlphaScreen-based FcRn b
assay due to the avidity effects by HMWS (Fig. 3A). To s
effects of oxidation in the binding of mAb1 Fc to FcRn, the
samples were also tested using SPR analysis as an ortho
testingmethod, whichwas intentionally designed in awa
only the 1:1 FcRn:IgG interaction is being examined in or
rule out the avidity effects. The data revealed that the
AAPH treated samples bind to FcRn at the levels compara
that of the control. The KD values (FcRn:mAb = 1
equilibrium for the control, 3 mM AAPH and 10 mM AAP
1.88 μM, 1.93 μM and 2.07 μM respectively. This indicate
oxidation of Met in this mAb1 AAPH treated samples h
impacts on 1:1 Fc to FcRn binding and the increased b
activity observed in the AlphaScreen-based FcRn binding
is from the avidity effects of the aggregates.
As described by Stracke et al. (2014), with the tw
residues present in each of the two heavy chains of an ant
four oxidation sites exist in the IgG Fc, giving rise to a t
ten Fc oxidation variants containing zero to fourMet oxid
per molecule. They found that antibody preparations
relatively high Fc Met oxidation levels (e.g. 40% oxMet25
25% oxMet428) do not show markedly impaired pharm
netic profiles (Stracke et al., 2014).
We also applied thismethod to characterizeminor an
variants of mAb1. During manufacture of therapeutic an
ies, various forms of microheterogeneity, including
charge, glycation, free thiol, and others, occur due to enzy
processes or spontaneous degradation and modifica
During this study, severalminor variants ofmAb1were is
to characterize their binding to FcRn. Each variant wass
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acidic variants), free thiol, and glycation variants demons
similar FcRn binding activities as did the reference m
(activities ranging from 91% to 110%). The basic variant,
contains a higher level of oxidation, was shown to have s
binding activities to the main peak. This is consistent wi
findings of Khawli et al. (2010), which demonstrated c
variants of IgGs do not affect the in vitro potency, FcRn b
affinity, or pharmacokinetic properties in rats.
3.2. General assay platform for applications in other mol
characterization studies
3.2.1. YTE mutation of IgG1 molecule (mAb2)
Modulating FcRn-IgG interaction allows changin
therapeutic antibody's half-life and improving its ef
there are several strategies for engineering IgGmAbs for
FcRn binding and increased pharmacokinetic property (
et al., 2013; Roopenian and Akilesh, 2007). For exa
various mutations at Thr250, Met252, Ser254, Thr307, G
Met428, His433, and Asn434 improve the pH-depe
binding of IgG to FcRn (Dall'Acqua et al., 2006; Hinton
2004, 2005; Kamei et al., 2005; Petkova et al., 2006; S
et al., 2001; Vaccaro et al., 2005). Also, YTE triple mu
(M252Y/S254T/T256E) in the CH2 domain of Fc is kno
increase the binding of palivizumab to human FcRn by
10-fold (Dall'Acqua et al., 2006). In order to assess wheth
AlphaScreen-based FcRn binding assay can detect the
tions in IgG Fc region, IgG1 mAb2 wild type and its YTE m
sample were tested side by side. The results showed th
mutation did increase FcRn binding by about 6-fold (Fig.
demonstrated that the AlphaScreen-based FcRn binding
can detect the FcRn binding change caused by YTE mu
and potentially could be used to screen IgG mAbs engin
for better FcRn binding.
3.2.2. Applications to other IgG isotypes
In order to evaluate whether the method can be use
general platform for other molecules, two additional
molecules (mAb4, mAb5) with the same antibody fram
and one IgG4 molecules (mAb6) were tested in this assay
platform. The results demonstrated that the assay platform is
Usin
t IgG1
mAbs having the same IgG Fc framework exhibit different FcRn
binding activities suggesting that the different Fab of IgG mAbs
show
ion or
Fig. 3. Biological characterization of IgG1mAb1 for FcRn binding. (A) Stressed sample panel of IgG1mAb in thermal, oxidation, and light stressed conditions. (B) Minor
variants of IgG1 mAb1 for different size, charge, disulfide bond, and glycosylation level.
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SPR analysis, it had been shown (Wang et al., 2011) thag may impact Fc-FcRn interaction as well. These results
that Fab potentially could induce different Fc conformat
indirectly alter the accessibility of Fc to FcRn for binding. In the
AlphaScreen-based FcRn assay shownhere, although bothmAb4
FcR
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aptur
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was demonstrated to be precise and accurate, and it was able to
detect changes in FcRn binding under different stress condi-
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Fig. 4. Applications to other IgGmolecules. (A) Effect of YTEmutation (open squares) for IgG1mAb2wild type (filled circle) in FcRn binding. (B) Application of AlphaScreen-
based FcRn binding assay to different IgG1 antibodies with the same framework (mAb4, open squares; mAb5 filled triangles) and IgG4 (mAb6, filled circles).
36 Q. Wu et al. / Journal of Immunological Methods 420 (2015) 31–37and mAb5 have the same IgG Fc framework, different
binding activities were observed, as indicated by the s
binding curve. There was little difference in HMWS inmAb
mAb5with 2.3% and 2% respectively. These results demons
that this AlphaScreen-based FcRn binding assay could c
potential conformational changes induced by the Fab tom
their impact on FcRn binding.
4. Conclusion
Ahomogeneous AlphaScreen-based FcRn binding assa
successfully developed and evaluated as a general
platform, which is simple, quick, and ready to apply to dif
types of IgG molecules with minimal modification. Then
f
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tions. Furthermore, the assay shows specific interaction o
to certain IgG isotypes (IgG1 and IgG4) but not to th
fragment. Different antibodies within the same IgG is
were shown to have different binding affinities in the
indicating the impact of the Fab portion of the antibody.
mutations known to affect FcRn binding, we could dete
altered binding of FcRn to IgG mutants. Due its simplici
high-throughput capability, the assay was successfully u
support various studies.
FcRn is a critical contributor to the half-life of thera
antibodies. An accurate, precise, specific, and user-fr
in vitro FcRn binding assay is a current need industry
It would facilitate the support of antibody engine
process development, comparability studies, and biol
characterization of pharmaceutical molecules. The method we
present here provides a platform approach that can be readily
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